Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): A large propensity score-matched population-based study

Hypomethylating agents (HMA) showed overall survival (OS) benefits in patients with higher-risk myelodysplastic syndromes (HR-MDS) in clinical trials. We conducted a retrospective cohort study of Surveillance, Epidemiology, and End Results (SEER)-Medicare data of patients ≥66 years diagnosed with re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Lymphoma
Main Authors: Davidoff, Amy J., Hu, Xin, Bewersdorf, Jan Philipp, Wang, Rong, Podoltsev, Nikolai A., Huntington, Scott F., Gore, Steven D., Ma, Xiaomei, Zeidan, Amer M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7735409/
https://ncbi.nlm.nih.gov/pubmed/31878809
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2019.1703970
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados